The Department, taking into consideration the recommendations of its Prescription Monitoring Program Advisory Committee, may issue a rule scheduling a substance in Schedule IV if it finds that:

1. (1) the substance has a low potential for misuse relative to substances in Schedule III;
2. (2) the substance has currently accepted medical use in treatment in the United States; and
3. (3) misuse of the substance may lead to limited physiological dependence or psychological dependence relative to the substances in Schedule III.

(from Ch. 56 1/2, par. 1209)

(Source: P.A. 103-881, eff. 1-1-25.)